Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia

Blood

Volumn 93, Issue 9, 1999, Pages 2817-2823

  Relling, Mary V ^a   Hancock, Michael L ^b   Boyett, James M ^b   Pui, Ching Hon ^b   Evans, William E ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; MERCAPTOPURINE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; TENIPOSIDE; THIOGUANOSINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

EID: 0033135738     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.9.2817.409k04_2817_2823     Document Type: Article

References (24)

1. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225, 1990
2. Schmiegelow K, Schroder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L, Schroder H: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13:345, 1995
3. Graham ML, Shuster JJ, Kamen BA, Cheo DL, Harrison MP, Leventhal BG, Pullen DJ, Whitehead VM: Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: A Pediatric Oncology Group pilot study. Cancer Chemother Pharmacol 31:217, 1992
4. Lilleyman JS, Lennard L: Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343:1188, 1994
5. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499, 1998
6. Lennard L: Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 423:169, 1987
7. Lennard L, Singleton HJ: High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: Quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 583:83, 1992
8. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui C-H, Evans WE: Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996, 1994
9. McLeod HL, Lin JS, Scott EP, Pui C-H, Evans WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55:15, 1994
10. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui C-H, Relling MV, Evans WE: Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608, 1997
11. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119:985, 1991
12. Cox DR: Regression models and life tables. J R Stat Soc B34:187, 1972
13. Kalbfleisch JD, Prentice RL: Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980, p 84
14. Hale JP, Lilleyman JS: Importance of 6-mercaptopurine dose in lymphoblastic leukaemia. Arch Dis Child 64:164, 1991
15. Schmiegelow K: Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 8:301, 1991
16. Dibenedetto SP, Guardabasso V, Ragusa R, Di Cataldo A, Miraglia V, D'Amico S, Ippolito AM: 6-Mercaptopurine cumulative dose: A critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 11:251, 1994
17. Elion GB: The purine path to chemotherapy. Science 24:441, 1989
18. Schmiegelow K, Pulczynska MK: Maintenance chemotherapy for childhood acute lymphoblastic leukemia: Should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol 12:462, 1990
19. Lucas K, Gula MJ, Blatt J: Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy. Pediatr Hematol Oncol 9:91, 1992
20. Welch JC, Lilleyman JS: 6-Mercaptopurine dose escalation and its effect on drug tolerance in childhood lymphoblastic leukaemia. Cancer Chemother Pharmacol 38:113, 1996
21. Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM: Continuing (maintenance) therapy in lymphoblastic leukaemia: Lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 98:945, 1997
22. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651, 1980
23. Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS: Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol 29:252, 1997
24. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K: Pharmacokinetics, dose adjustments, and 6-mercaptopurine/ methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 87:108, 1998